electroCore (NASDAQ:ECOR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Key Points

• electroCore reported third-quarter EPS of -$0.13, beating the consensus estimate of -$0.27 by $0.14. Revenue was $9.69 million, below the $10.93 million analyst estimate; sales rose 12% year over year and gross margin reached 88.5%.
• The company cut its 2026 revenue outlook to $39 million–$42 million, citing delays from sales-force changes. Management expects 30%–40% revenue growth in 2027 and is targeting its first positive Adjusted EBITDA quarter by year-end 2027.
• Cash and marketable securities declined to $7.5 million, and electroCore is considering a term-loan refinancing with no agreement yet. A pending FDA submission for Quell could open a new treatment market, but clearance and sales are uncertain.

electroCore (NASDAQ:ECOR - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.14, FiscalAI reports. The business had revenue of $9.69 million during the quarter, compared to analyst estimates of $10.93 million.

Here are the key takeaways from electroCore's conference call:

• electroCore reported record third-quarter net sales of $9.7 million, up 12% year over year, with gross margin expanding to 88.5%. Adjusted EBITDA loss narrowed to a company-low $700,000, although GAAP results included a $400,000 settlement gain and a $100,000 tax benefit.
• The company lowered its 2026 revenue outlook to $39 million–$42 million, saying sales-force changes delayed the acceleration it had expected in the second half. Management now anticipates 30%–40% revenue growth in 2027 and targets its first positive Adjusted EBITDA quarter by year-end 2027, both dependent on execution.
• Management cited early gains from its commercial overhaul: newer representatives generated about 30% more monthly VA revenue than the territories did before, and VA new-patient orders rose 21% year over year. Refill revenue reached a company high, while the national refill rate was 42% through September, below the company’s goal of more than 70%.
• electroCore filed an FDA 510(k) submission for Quell to treat chemotherapy-induced peripheral neuropathy (CIPN), a potential new market that management estimates at 600,000–700,000 U.S. patients. Clearance and any resulting sales remain uncertain; the company said CIPN-specific revenue is not included in its 2027 growth outlook.
• Cash, cash equivalents, and marketable securities fell to $7.5 million from $10 million at the end of the prior quarter. The company is evaluating a term-loan refinancing to support its runway, but said it has no agreement in place.

electroCore Price Performance

NASDAQ ECOR traded up $1.17 on Wednesday, hitting $8.40. 235,534 shares of the company were exchanged, compared to its average volume of 79,272. The company's 50 day moving average price is $9.36 and its 200-day moving average price is $7.75. The firm has a market capitalization of $75.77 million, a P/E ratio of -5.06 and a beta of 1.23. electroCore has a twelve month low of $4.41 and a twelve month high of $12.70.

Insider Transactions at electroCore

In other news, Director Thomas Errico purchased 5,000 shares of the business's stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of $9.82 per share, for a total transaction of $49,100.00. Following the completion of the acquisition, the director directly owned 363,904 shares of the company's stock, valued at $3,573,537.28. The trade was a 1.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Joshua S. Lev sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total transaction of $28,080.00. Following the sale, the chief financial officer owned 84,889 shares in the company, valued at $794,561.04. This represents a 3.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,000 shares of company stock valued at $200,120 over the last ninety days. Insiders own 7.80% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of electroCore in a research note on Monday, September 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $18.00.

electroCore Company Profile

electroCore, Inc NASDAQ: ECOR is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company's primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.